The condensed consolidated financial statements of Humana Inc. in this document
present the Company's financial position, results of operations and cash flows,
and should be read in conjunction with the following discussion and analysis.
References to "we," "us," "our," "Company," and "Humana" mean Humana Inc. and
its subsidiaries. This discussion includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. When used in
filings with the Securities and Exchange Commission, or SEC, in our press
releases, investor presentations, and in oral statements made by or with the
approval of one of our executive officers, the words or phrases like "believes,"
"expects," "anticipates," "intends," "likely will result," "estimates,"
"projects" or variations of such words and similar expressions are intended to
identify such forward-looking statements. These forward-looking statements are
not guarantees of future performance and are subject to risks, uncertainties and
assumptions, including, among other things, information set forth in Item 1A. -
Risk Factors in our 2019 Form 10-K, as modified by any changes to those risk
factors included in this document including the potential impacts of risks
related to the spread of, and response to, the COVID-19 pandemic as further
discussed in Part II of this report and in other reports we filed subsequent to
February 20, 2020, in each case incorporated by reference herein. In making
these statements, we are not undertaking to address or update such
forward-looking statements in future filings or communications regarding our
business or results. In light of these risks, uncertainties and assumptions, the
forward-looking events discussed in this document might not occur. There may
also be other risks that we are unable to predict at this time. Any of these
risks and uncertainties may cause actual results to differ materially from the
results discussed in the forward-looking statements.
Executive Overview
General
Humana Inc., headquartered in Louisville, Kentucky, is a leading health and
well-being company committed to helping our millions of medical and specialty
members achieve their best health. Our successful history in care delivery and
health plan administration is helping us create a new kind of integrated care
with the power to improve health and well being and lower costs. Our efforts are
leading to a better quality of life for people with Medicare, families,
individuals, military service personnel, and communities at large. To accomplish
that, we support physicians and other health care professionals as they work to
deliver the right care in the right place for their patients, our members. Our
range of clinical capabilities, resources and tools, such as in home care,
behavioral health, pharmacy services, data analytics and wellness solutions,
combine to produce a simplified experience that makes health care easier to
navigate and more effective.
Our industry relies on two key statistics to measure performance. The benefit
ratio, which is computed by taking
total benefits expense as a percentage of premiums revenue, represents a
statistic used to measure underwriting profitability. The operating cost ratio,
which is computed by taking total operating costs, excluding depreciation and
amortization, as a percentage of total revenue less investment income,
represents a statistic used to measure administrative spending efficiency.
COVID-19
We have continued to take actions to protect, inform, and care for our members,
providers, employees, and other stakeholders associated with the outbreak of the
novel coronavirus, or COVID-19. Specifically, we have taken the following
actions to support our members:

•waiving all cost sharing for in-network primary care, outpatient behavioral health, and telehealth visits for the remainder of 2020 for our Medicare Advantage members, to reduce financial barriers to members seeking to re-engage with their providers, while continuing to encourage the use of telehealth;

•delivering meals to our senior members in need;

•making it easier for members to be tested for COVID-19 by offering at-home testing, as well as collaborating with other providers to deploy drive-thru testing at hundreds of sites throughout the country;


                                       35

--------------------------------------------------------------------------------

Table of Contents

•mailing in-home screening kits to members, to encourage members to seek preventative care that may have been delayed during the pandemic;

•proactively delivering safety kits, including face masks, to members and employee homes to facilitate access to care and support visits to providers safely;

•continuing to extend grace periods for premium payments for our fully-insured commercial group members, to ensure continuity of coverage during times of financial stress; and

•establishing a clinical outreach team to proactively engage with our most vulnerable members.



In addition, we took steps to support our provider partners and boost system
viability:
•increasing provider funding, simplifying and expanding claims processing and
releasing advanced funding to providers, to get reimbursement payments to
providers as quickly as possible and ease financial concerns so that members are
able to continue to access the care and information they need; and
•expanding modifications to certain utilization management processes, to ease
administrative stress and make sure providers are able to most efficiently care
for their patients.
Finally, we continued to support the communities we serve by donating $200
million during the first half of 2020 to the Humana Foundation to address social
determinants of health in an effort to promote more health days and encourage
greater health equity.
The temporary deferral of non-essential care resulting from stay-at-home and
physical distancing orders and other restrictions on movement and economic
activity implemented throughout the country beginning in the second half of
March 2020 to reduce the spread of the novel coronavirus, or COVID-19, has
impacted our business. Hospital admissions and utilization were significantly
depressed in April and increased throughout May and June. Utilization continued
to rebound throughout the third quarter of 2020, reaching approximately 95% of
historic baseline levels at the close of the third quarter. The impact of the
deferral of non-essential care was partially offset by COVID-19 testing and
treatment costs, as well as our ongoing pandemic relief efforts.

We significantly increased our liquidity position during March 2020 with the issuance of $1.1 billion in senior notes and a $1 billion draw under the prior one-year term loan bank commitment. At September 30, 2020, we held $2.4 billion of cash and short-term investments at our parent company and access to an additional $2.0 billion under our credit agreement. For the remainder of 2020, we expect our year to date 2020 performance will be further offset by the impact of increasing utilization, COVID-19 testing and treatment costs and the continued support for our constituents. A number of significant variables and uncertainties will impact these trends including, among others, the severity and duration of the pandemic, continued actions taken to mitigate the spread of COVID-19 and in turn, relax those restrictions, the timing and degree in resumption of demand for deferred health care services, the ability of our commercial members to pay their premium, the nature, level and cost of diagnostic testing, the cost and timing of new therapeutic treatments and vaccines, all of which are difficult to predict. As such, our response to this global health crisis and the subsequent recovery will continue to evolve over the coming months to support the needs of our stakeholders.

Recent Transactions In the first quarter of 2020, we purchased privately held Enclara, one of the nation's largest hospice pharmacy and benefit management providers, for cash consideration of approximately $709 million, net of cash received.


                                       36

--------------------------------------------------------------------------------


  Table of Contents
We have entered into a strategic partnership with WCAS to accelerate the
expansion of our primary care model. The WCAS partnership is expected to open
approximately 50 payor-agnostic, senior-focused primary care centers over 3
years beginning in 2020.
These transactions are more fully discussed in Note 3 to the condensed
consolidated financial statements.
Business Segments
We manage our business with three reportable segments: Retail, Group and
Specialty, and Healthcare Services. The reportable segments are based on a
combination of the type of health plan customer and adjacent businesses centered
on well-being solutions for our health plans and other customers, as described
below. These segment groupings are consistent with information used by our Chief
Executive Officer, the Chief Operating Decision Maker, to assess performance and
allocate resources.
The Retail segment consists of Medicare benefits, marketed to individuals or
directly via group Medicare accounts. In addition, the Retail segment also
includes our contract with CMS to administer the Limited Income Newly Eligible
Transition, or LI-NET, prescription drug plan program and contracts with various
states to provide Medicaid, dual eligible, and Long-Term Support Services
benefits, which we refer to collectively as our state-based contracts. The Group
and Specialty segment consists of employer group commercial fully-insured
medical and specialty health insurance benefits marketed to individuals and
employer groups, including dental, vision, and other supplemental health
benefits, as well as administrative services only, or ASO products. In addition,
our Group and Specialty segment includes our military services business,
primarily our TRICARE T2017 East Region contract. The Healthcare Services
segment includes our services offered to our health plan members as well as to
third parties, including pharmacy solutions, provider services, and clinical
care service, such as home health and other services and capabilities to promote
wellness and advance population health, including our minority investment in
Kindred at Home and the strategic partnership with WCAS to develop and operate
senior-focused, payor-agnostic, primary care centers.
The results of each segment are measured by segment earnings, and for our
Healthcare Services Segment, also include equity in net earnings from our equity
method investees. Transactions between reportable segments primarily consist of
sales of services rendered by our Healthcare Services segment, primarily
pharmacy, provider, and clinical care services, to our Retail and Group and
Specialty segment customers. Intersegment sales and expenses are recorded at
fair value and eliminated in consolidation. Members served by our segments often
use the same provider networks, enabling us in some instances to obtain more
favorable contract terms with providers. Our segments also share indirect costs
and assets. As a result, the profitability of each segment is interdependent. We
allocate most operating expenses to our segments. Assets and certain corporate
income and expenses are not allocated to the segments, including the portion of
investment income not supporting segment operations, interest expense on
corporate debt, and certain other corporate expenses. These items are managed at
a corporate level. These corporate amounts are reported separately from our
reportable segments and are included with intersegment eliminations.
Seasonality
One of the product offerings of our Retail segment is Medicare stand-alone
prescription drug plans, or PDPs, under the Medicare Part D program. Our
quarterly Retail segment earnings and operating cash flows are impacted by the
Medicare Part D benefit design and changes in the composition of our membership.
The Medicare Part D benefit design results in coverage that varies as a member's
cumulative out-of-pocket costs pass through successive stages of a member's plan
period, which begins annually on January 1 for renewals. These plan designs
generally result in us sharing a greater portion of the responsibility for total
prescription drug costs in the early stages and less in the latter stages. As a
result, the PDP benefit ratio generally decreases as the year progresses. In
addition, the number of low income senior members as well as year-over-year
changes in the mix of membership in our stand-alone PDP products affects the
quarterly benefit ratio pattern.
In addition, the Retail segment also experiences seasonality in the operating
cost ratio as a result of costs incurred in the second half of the year
associated with the Medicare marketing season.
                                       37

--------------------------------------------------------------------------------


  Table of Contents
Our Group and Specialty segment also experiences seasonality in the benefit
ratio pattern. However, the effect is opposite of Medicare stand-alone PDP in
the Retail segment, with the Group and Specialty segment's benefit ratio
increasing as fully-insured members progress through their annual deductible and
maximum out-of-pocket expenses.
2020 Highlights
•Our strategy offers our members affordable health care combined with a positive
consumer experience in growing markets. At the core of this strategy is our
integrated care delivery model, which unites quality care, high member
engagement, and sophisticated data analytics. Our approach to primary,
physician-directed care for our members aims to provide quality care that is
consistent, integrated, cost-effective, and member-focused, provided by both
employed physicians and physicians with network contract arrangements. The model
is designed to improve health outcomes and affordability for individuals and for
the health system as a whole, while offering our members a simple, seamless
healthcare experience. We believe this strategy is positioning us for long-term
growth in both membership and earnings. We offer providers a continuum of
opportunities to increase the integration of care and offer assistance to
providers in transitioning from a fee-for-service to a value-based arrangement.
These include performance bonuses, shared savings and shared risk relationships.
At September 30, 2020, approximately 2,605,900 members, or 66%, of our
individual Medicare Advantage members were in value-based relationships under
our integrated care delivery model, as compared to 2,340,600 members, or 66%, at
September 30, 2019. Medicare Advantage and dual demonstration program membership
enrolled in a Humana chronic care management program was 917,200 at
September 30, 2020, an increase of 4% from 882,800 at September 30, 2019. These
members may not be unique to each program since members have the ability to
enroll in multiple programs. The increase is driven by our improved process for
identifying and enrolling members in the appropriate program at the right time,
coupled with growth in Special Needs Plans, or SNP, membership.
•In October, 2020, the Centers for Medicare and Medicaid Services, or CMS,
issued its preliminary 2022 Medicare Advantage and Part D payment rates and
proposed policy changes, collectively, the Advance Notice. CMS has invited
public comment on the Advance Notice before publishing final rates on or before
April 5, 2021, or the Final Notice, and indicated that the Final Notice may be
published early in light of the challenges posed by the uncertainty associated
with the COVID-19 pandemic. In the Advance Notice, CMS estimates Medicare
Advantage plans across the sector will, on average, experience a 2.82 percent
increase in benchmark funding based on proposals included therein. As indicated
by CMS, its estimate excludes the impact of fee-for-service county
rebasing/re-pricing since the related impact is dependent upon finalization of
certain data, which will be available with the publication of the Final Notice.
Based on our preliminary analysis using the same factors CMS included in its
estimate, the components of which are detailed on CMS' website, we anticipate
the proposals in the Advance Notice would result in a change generally in line
with CMS' estimate, with the exception of our Medicare Star Ratings for bonus
year 2022, as more fully described below, that led our peers. We will be drawing
upon our program expertise to provide CMS formal commentary on the impact of the
Advance Notice and the related impact upon Medicare beneficiaries' quality of
care and service to our members through the Medicare Advantage program.
•In October 2020, CMS published its updated Medicare Star Ratings for bonus year
2022.We have 4.1 million members, or approximately 92 percent of our Medicare
Advantage membership as of September 2020, enrolled in 15 contracts that
received a 4-star rating or above. In addition, we received a 5 out of 5-star
rating for our CarePlus Health Plans, Inc. contract in Florida for the third
consecutive year and received a 4.5-star rating for three Medicare Advantage
contracts offered in 7 states, which cover approximately 796,000 members.
Additionally, over 99 percent of retirees in our group Medicare Advantage plans
remain in 4-star or above contracts for bonus year 2022. Our Star Ratings
continue to reflect our focus on quality in both member experience and clinical
outcomes.
•Net income was $1.3 billion, or $10.05 per diluted common share, for the three
months ended September 30, 2020, or the 2020 quarter, compared to $689 million,
or $5.14 per diluted common share, for the three months ended September 30,
2019, or the 2019 quarter, and was $3.6 billion, or $27.37 per diluted
                                       38

--------------------------------------------------------------------------------

Table of Contents common share, for the nine months ended September 30, 2020, or the 2020 period, compared to $2.2 billion, or $16.24 per diluted common share, for the nine months ended September 30, 2019, or the 2019 period. These comparisons were significantly impacted by the change in the fair value of publicly-traded equity securities, the net receipt of commercial risk corridor receivables previously written off, and the put/call valuation adjustments associated with certain equity method investments. The change in the fair value of our publicly-traded equity securities relates primarily to our common stock holdings, including both the gain resulting from the initial conversion of our prior ownership interest in certain privately held companies, primarily in Oak Street Health, Inc., or OSH, into common stock upon such companies' initial public offering, or IPO, during the third quarter of 2020, and the subsequent changes in the market value of such securities from their IPO through the end of the period. In September 2020, we received $578 million, net of related fees and expenses pursuant to the U.S. Supreme Court ruling that the government is obligated to pay the losses under the risk corridor program. The receipt of the risk corridor payments was associated with losses incurred under the Health Care Reform business in 2014 to 2016. The receipt of these risk corridor payments accounted for less than half of our accumulated losses before income taxes from this business during that time period. The impact of these adjustments to our consolidated income before income taxes and equity in net earnings and diluted earnings per common share was as follows for the 2020 quarter and period.

© Edgar Online, source Glimpses